Trials / Completed
CompletedNCT00550303
Study Comparing Formulations of Bazedoxifene/Conjugated Estrogens
An Open-Label, Single-Dose, Non-Randomized, 4-Period Crossover Bioavailability Study of Bazedoxifene Contained in Bazedoxifene/Conjugated Estrogen Tablets Administered to Healthy Postmenopausal Women
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Female
- Age
- 45 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The primary purpose is to determine bioavailability of Bazedoxifene/conjugated estrogen formulations for future testing purposes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bazedoxifene/conjugated estrogens combination |
Timeline
- Start date
- 2007-10-01
- Completion
- 2007-11-01
- First posted
- 2007-10-29
- Last updated
- 2007-12-27
Source: ClinicalTrials.gov record NCT00550303. Inclusion in this directory is not an endorsement.